Mylan NV (NASDAQ: MYL), a global pharmaceutical company, is launching its Mesalamine Delayed-Release Tablets USP, 1.2g, a generic version of Shire's Lialda Delayed-Release Tablets, in the US.
It was reported yesterday that the company received final approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product that is indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis and for the maintenance of remission of ulcerative colitis.
Presently, the company has 168 ANDA's pending US FDA approval, representing around USD85.5bn in annual brand sales, according to IQVIA. Forty-four of these pending ANDA's are potential first-to-file opportunities, representing USD50.4bn in annual brand sales, for the 12 months ending 30 June 2018, according to IQVIA.
Par Health launches generic version of Janumet XR tablets in US
EQL Pharma gains approval to sell Mellozzan in Kazakhstan
Newbury Pharmaceuticals receives Swedish approval for generic tofacitinib
Breckenridge launches Tofacitinib Tablets, generic equivalent to Pfizer's Xeljanz
Hims & Hers expands GLP-1 offering in Canada with generic semaglutide
Apotex announces commercial launch of Apo-Semaglutide Injection in Canada
Transpire Bio's generic high-strength Trelegy Ellipta ANDA accepted for filing by US FDA
Kaiser Permanente reports study findings showing significant cost savings
Apotex receives Health Canada approval for a generic Ozempic equivalent
Cipla's AB-rated Ventolin HFA generic receives US FDA approval
Newbury Pharmaceuticals secures first Scandinavian approval for palbociclib generic
Apotex's generic Ozempic (Semaglutide Injection) receives US FDA tentative approval
DifGen and Apotex report FDA approval of generic Nintedanib Soft Gel Capsules